Dr. Manne obtained his M.S. (Biochemistry, Histochemistry, Parasitology, Zoonosis) and Ph.D. (energy metabolic pathways of endoparasites) degrees from Osmania University, Hyderabad, India. His postdoctoral training was in molecular immunology and vaccine development for malaria (Malaria Research Center, Delhi, India); in helicobacter infections (School of Microbiology, University of New South Wales, Sydney, Australia); and in histopathology, molecular tumor biology, and preclinical translational research of human malignancies at the University of Alabama at Birmingham (UAB). He also received certification in bioinformatics at UAB. Dr. Manne’s research on racial disparity in CRC has received considerable national and international recognition. In 2009, the Presidents Cancer Panel invited Dr. Manne to speak on “Biologic differences between ethnic groups and their clinical implications in cancer care,” and devoted to the topic, “America’s demographic and cultural transformation: implications for the cancer enterprise.” Currently, he is the Lead Principal Investigator of two Comprehensive Cancer Research Partnership between UAB Comprehensive Cancer Center and Tuskegee University, Tuskegee, AL and Morehouse School of Medicine, Atlanta, GA (U54); and Alabama State University, Montgomery, AL (P20) to Reduce Cancer Health Disparities by implementing innovative, multi-disciplinary, collaborative, population-based cancer control and prevention research and has contributed to education, training, and community outreach activities. These two programs are funded by the National Cancer Institute of the National Institute of Health.
Translational research in grastrointestinal malignancies and breast cancer - Dr. Manne’s present efforts are focused on population-based translational research for human neoplasias, with emphasis on colorectal and breast cancers. His laboratory, with projects funded by the National Cancer Institute and the Susan G. Komen Foundation, is evaluating molecular markers to identify aggressive phenotypic features of tumors to predict the efficacy of chemotherapeutic regimens and to assess clinical outcomes. Dr. Manne’s research and collaborative groups include experts in the fields of molecular biology, clinical oncology, pathology, epidemiology, statistics, and bioinformatics. For evaluating the clinical utility of genetic and phenotypic abnormalities in colorectal cancer, his group has developed strategies demonstrating that the utility of molecular biomarkers varies according to the anatomic location of tumors within the colorectum and with tumor stage, race/ethnicity, age, and gender. To validate the clinical utility of genetic and phenotypic markers, Dr. Manne’s laboratory is evaluating hundreds of colorectal cancer samples derived from African American and non-Hispanic Caucasian ethnic/racial backgrounds and collected from different institutions. Established molecular markers with be merged with other epidemiological, environmental, and socio-economic features to find the basis for racial disparities in colorectal and breast malignancies. Results from approaches involving biomarker discovery and bioinformatics will aid in developing predictive models specific for individual patients. The research interests of Dr. Manne also include use of genomics and proteomics for identification of early markers of cancers, specifically, identification of molecular signatures of benign colonic epithelium, which is at risk of developing colorectal neoplasias, and of other pre-malignant lesions. These studies will aid in the evaluation of molecular and pathologic characteristics of specimens and in the development of assays that relate to early detection, diagnosis, prognosis, and treatment of cancers.
Keywords - Colorectal Cancer, Breast Cancer, Molecular Biomarkers, Racial/Ethnic Disparities, Cancer Control & Prevention